S&P 500   4,304.00 (+0.69%)
DOW   33,678.23 (+0.38%)
QQQ   357.90 (+0.81%)
AAPL   170.62 (+0.11%)
MSFT   313.69 (+0.29%)
META   302.89 (+1.73%)
GOOGL   132.34 (+1.38%)
AMZN   125.87 (-0.09%)
TSLA   246.13 (+2.34%)
NVDA   431.38 (+1.58%)
NIO   8.93 (+5.56%)
BABA   85.49 (-0.81%)
AMD   102.66 (+4.68%)
T   14.95 (+0.54%)
F   12.56 (+1.37%)
MU   65.04 (-4.65%)
CGC   0.82 (-7.97%)
GE   112.26 (+1.24%)
DIS   80.02 (+0.15%)
AMC   7.68 (+1.45%)
PFE   31.99 (-0.34%)
PYPL   58.04 (+1.22%)
NFLX   375.86 (-0.46%)
S&P 500   4,304.00 (+0.69%)
DOW   33,678.23 (+0.38%)
QQQ   357.90 (+0.81%)
AAPL   170.62 (+0.11%)
MSFT   313.69 (+0.29%)
META   302.89 (+1.73%)
GOOGL   132.34 (+1.38%)
AMZN   125.87 (-0.09%)
TSLA   246.13 (+2.34%)
NVDA   431.38 (+1.58%)
NIO   8.93 (+5.56%)
BABA   85.49 (-0.81%)
AMD   102.66 (+4.68%)
T   14.95 (+0.54%)
F   12.56 (+1.37%)
MU   65.04 (-4.65%)
CGC   0.82 (-7.97%)
GE   112.26 (+1.24%)
DIS   80.02 (+0.15%)
AMC   7.68 (+1.45%)
PFE   31.99 (-0.34%)
PYPL   58.04 (+1.22%)
NFLX   375.86 (-0.46%)
S&P 500   4,304.00 (+0.69%)
DOW   33,678.23 (+0.38%)
QQQ   357.90 (+0.81%)
AAPL   170.62 (+0.11%)
MSFT   313.69 (+0.29%)
META   302.89 (+1.73%)
GOOGL   132.34 (+1.38%)
AMZN   125.87 (-0.09%)
TSLA   246.13 (+2.34%)
NVDA   431.38 (+1.58%)
NIO   8.93 (+5.56%)
BABA   85.49 (-0.81%)
AMD   102.66 (+4.68%)
T   14.95 (+0.54%)
F   12.56 (+1.37%)
MU   65.04 (-4.65%)
CGC   0.82 (-7.97%)
GE   112.26 (+1.24%)
DIS   80.02 (+0.15%)
AMC   7.68 (+1.45%)
PFE   31.99 (-0.34%)
PYPL   58.04 (+1.22%)
NFLX   375.86 (-0.46%)
S&P 500   4,304.00 (+0.69%)
DOW   33,678.23 (+0.38%)
QQQ   357.90 (+0.81%)
AAPL   170.62 (+0.11%)
MSFT   313.69 (+0.29%)
META   302.89 (+1.73%)
GOOGL   132.34 (+1.38%)
AMZN   125.87 (-0.09%)
TSLA   246.13 (+2.34%)
NVDA   431.38 (+1.58%)
NIO   8.93 (+5.56%)
BABA   85.49 (-0.81%)
AMD   102.66 (+4.68%)
T   14.95 (+0.54%)
F   12.56 (+1.37%)
MU   65.04 (-4.65%)
CGC   0.82 (-7.97%)
GE   112.26 (+1.24%)
DIS   80.02 (+0.15%)
AMC   7.68 (+1.45%)
PFE   31.99 (-0.34%)
PYPL   58.04 (+1.22%)
NFLX   375.86 (-0.46%)
NASDAQ:IONS

Ionis Pharmaceuticals (IONS) Competitors

$46.71
-0.42 (-0.89%)
(As of 02:10 PM ET)
Compare
Today's Range
$46.03
$47.20
50-Day Range
$38.50
$47.13
52-Week Range
$32.69
$47.74
Volume
988,669 shs
Average Volume
1.05 million shs
Market Capitalization
$6.69 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.10

IONS vs. ALKS, IMGN, FOLD, MDGL, UTHR, DVAX, ALNY, ELAN, RETA, and KRTX

Should you be buying Ionis Pharmaceuticals stock or one of its competitors? The main competitors of Ionis Pharmaceuticals include Alkermes (ALKS), ImmunoGen (IMGN), Amicus Therapeutics (FOLD), Madrigal Pharmaceuticals (MDGL), United Therapeutics (UTHR), Dynavax Technologies (DVAX), Alnylam Pharmaceuticals (ALNY), Elanco Animal Health (ELAN), Reata Pharmaceuticals (RETA), and Karuna Therapeutics (KRTX). These companies are all part of the "pharmaceutical preparations" industry.

Ionis Pharmaceuticals vs.

Ionis Pharmaceuticals (NASDAQ:IONS) and Alkermes (NASDAQ:ALKS) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

Alkermes has a net margin of 7.04% compared to Ionis Pharmaceuticals' net margin of -48.81%. Alkermes' return on equity of 2.33% beat Ionis Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Ionis Pharmaceuticals-48.81% -59.17% -11.40%
Alkermes 7.04%2.33%1.27%

Alkermes received 6 more outperform votes than Ionis Pharmaceuticals when rated by MarketBeat users. Likewise, 70.70% of users gave Alkermes an outperform vote while only 60.38% of users gave Ionis Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Ionis PharmaceuticalsOutperform Votes
660
60.38%
Underperform Votes
433
39.62%
AlkermesOutperform Votes
666
70.70%
Underperform Votes
276
29.30%

Alkermes has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ionis Pharmaceuticals$587M11.41-$269.72M-$2.17-21.53
Alkermes$1.11B4.25-$158.27M$0.5749.81

Ionis Pharmaceuticals currently has a consensus target price of $48.10, suggesting a potential upside of 2.98%. Alkermes has a consensus target price of $33.33, suggesting a potential upside of 17.41%. Given Alkermes' stronger consensus rating and higher possible upside, analysts clearly believe Alkermes is more favorable than Ionis Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ionis Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.44
Alkermes
0 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, Ionis Pharmaceuticals had 20 more articles in the media than Alkermes. MarketBeat recorded 22 mentions for Ionis Pharmaceuticals and 2 mentions for Alkermes. Alkermes' average media sentiment score of 0.94 beat Ionis Pharmaceuticals' score of 0.71 indicating that Alkermes is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ionis Pharmaceuticals
9 Very Positive mention(s)
4 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Positive
Alkermes
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Ionis Pharmaceuticals has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500.

93.9% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 2.7% of Ionis Pharmaceuticals shares are held by company insiders. Comparatively, 4.8% of Alkermes shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Alkermes beats Ionis Pharmaceuticals on 15 of the 18 factors compared between the two stocks.


Get Ionis Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IONS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IONS vs. The Competition

MetricIonis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$6.69B$6.11B$4.54B$6.27B
Dividend YieldN/A2.71%2.51%6.56%
P/E Ratio-21.534.77119.2811.81
Price / Sales11.41195.352,951.5662.79
Price / CashN/A22.6793.43100.64
Price / Book11.593.763.754.65
Net Income-$269.72M$198.10M$122.62M$186.05M
7 Day Performance9.96%4.43%1.58%0.33%
1 Month Performance14.32%-3.26%-1.84%-4.35%
1 Year Performance5.16%7.33%9.53%4.15%

Ionis Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALKS
Alkermes
2.2604 of 5 stars
$29.91
-0.1%
$33.33
+11.4%
+29.7%$4.98B$1.11B52.472,280
IMGN
ImmunoGen
2.6017 of 5 stars
$15.67
-0.3%
$22.88
+46.0%
+233.3%$3.90B$108.78M-21.76277Analyst Revision
FOLD
Amicus Therapeutics
2.1686 of 5 stars
$12.90
+0.2%
$15.20
+17.8%
+25.8%$3.70B$329.23M-20.16484Analyst Revision
News Coverage
Positive News
Trading Halted
MDGL
Madrigal Pharmaceuticals
2.5966 of 5 stars
$169.35
+3.5%
$309.18
+82.6%
+132.8%$3.13BN/A-9.0892Positive News
UTHR
United Therapeutics
2.9453 of 5 stars
$220.67
+1.5%
$296.44
+34.3%
+12.9%$10.36B$1.94B12.48985Positive News
DVAX
Dynavax Technologies
2.6359 of 5 stars
$13.73
+1.2%
$24.33
+77.2%
+38.7%$1.77B$722.68M19.07351Positive News
ALNY
Alnylam Pharmaceuticals
2.7039 of 5 stars
$175.66
-2.3%
$247.40
+40.8%
-12.7%$21.96B$1.04B-20.402,002Positive News
ELAN
Elanco Animal Health
1.963 of 5 stars
$11.85
+0.4%
$15.10
+27.4%
-13.0%$5.84B$4.42B-59.259,000
RETA
Reata Pharmaceuticals
2.096 of 5 stars
$172.11
+0.0%
$150.36
-12.6%
N/A$6.57B$2.22M0.00321
KRTX
Karuna Therapeutics
2.4267 of 5 stars
$174.64
+2.1%
$260.50
+49.2%
-24.7%$6.58B$10.64M-17.21210News Coverage
Positive News
Gap Up

Related Companies and Tools

This page (NASDAQ:IONS) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -